How to buy Mesoblast (MSB) shares
Learn how to easily invest in Mesoblast shares.
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Mesoblast Limited is a biotechnology business based in Australia. Mesoblast shares (MSB) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. Mesoblast has a trailing 12-month revenue of around $7.5 million. If you're looking to buy shares, check out the steps below.
How to buy shares in Mesoblast
- Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
- Search for Mesoblast. Find the share by name or ticker symbol: MSB. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Mesoblast reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
- Check in on your investment. Congratulations, you own a part of Mesoblast. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Mesoblast stock price (ASX:MSB)Use our graph to track the performance of MSB stocks over time.
Mesoblast shares at a glance
|52-week range||$1.57 - $5.7|
|50-day moving average||$1.8209|
|200-day moving average||$2.0034|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.224|
Compare share trading platforms
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Is it a good time to buy Mesoblast stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Mesoblast price performance over time
|1 week (2021-09-17)||4.88%|
|1 month (2021-08-25)||-15.69%|
|3 months (2021-06-25)||-20.37%|
|6 months (2021-03-25)||-26.18%|
|1 year (2020-09-25)||-64.97%|
|2 years (2019-09-25)||-14.00%|
|3 years (2018-09-25)||-8.02%|
|5 years (2016-09-23)||56.52%|
|Revenue TTM||$7.5 million|
|Gross profit TTM||$-78,275,000|
|Return on assets TTM||-9.22%|
|Return on equity TTM||-17.48%|
|Market capitalisation||$1.1 billion|
TTM: trailing 12 months
Mesoblast share dividends
We're not expecting Mesoblast to pay a dividend over the next 12 months.
Mesoblast share price volatility
Over the last 12 months, Mesoblast's shares have ranged in value from as little as $1.57 up to $5.7. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Mesoblast's is 2.4704. This would suggest that Mesoblast's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
Stocks similar to Mesoblast
Mesoblast in the news
Operational Highlights and Financial Results for the Year Ended June 30, 2021
Mesoblast Corporate Update and Financial Results Webcast
Mesoblast : Corporate Update and Financial Results Webcast
Frequently asked questions
More guides on Finder
How to invest in the Cosmos Exploration IPO
Everything we know about the Cosmos Exploration IPO, plus information on how to buy in.
What is behind the bounce in the Zip Co share price?
Shares in BNPL provider Zip Co have slipped more than 13% in the last 6 months.
Why the AGL share price has rebounded today
Shares in electricity giant AGL Energy are down 60% in the last 12 months.
How to invest in the Dundas Minerals IPO
Everything we know about the Dundas Minerals IPO, plus information on how to buy in.
How to invest in the Kalgoorlie Gold Mining IPO
Everything we know about the Kalgoorlie Gold Mining IPO, plus information on how to buy in.
The best iron ore stocks on the ASX (2021)
We look at some of the biggest and best performing iron ore stocks in Australia.
Why are the CBA and WBC share prices stumbling today?
Shares in the major banks have risen more than 50% in the last 12 months.
How to buy Evergrande shares from Australia
Steps to owning and managing China Evergrande Group shares from Australia.
Virgin Tasmania flights sale from $49 and double status credits
Virgin Australia launches more direct Tassie services with flexible flights taking off from October 2021.
How to invest in the Hamelin Gold IPO
Everything we know about the Hamelin Gold IPO, plus information on how to buy in.
Ask an Expert